Merck KGaA and Pfizer agree to terminate the JAVELIN Head and Neck 100 trial of Bavencio as unlikely to show a statistically significant improvement in progression-free survival.
Related news and insights
A report from the Institute of Cancer Research showed an immunotherapy combination could be better than standard ‘Extreme’ chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III trial suggests.
PDS Biotechnology Corporation announced that it has completed the enrollment of the lead-in safety cohort of its VERSATILE-002 Phase II study evaluating the efficacy and safety of the combination of PDS 0101, a clinical stage immunotherapy to treat cancers caused by infection with the human papillomavirus (HPV), and Keytruda (pembrolizumab), a checkpoint inhibitor (CPI)
GlaxoSmithKline plc announced, following a recommendation by the Independent Data Monitoring Committee, that it has taken the decision to stop enrolling patients in the phase II INDUCE-3 trial , including discontinuing treatment with feladilimab.